Trials / Completed
CompletedNCT01253525
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ramucirumab (IMC-1121B ) | 8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle |
| DRUG | Paclitaxel | 80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-12-03
- Last updated
- 2014-06-18
- Results posted
- 2014-06-18
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01253525. Inclusion in this directory is not an endorsement.